Corrected: BUZZ-AstraZeneca rises after Q3 results beat, launches $1.5 billion annual savings plan
CORRECTED-BUZZ-AstraZeneca rises after Q3 results beat, launches $1.5 billion annual savings plan Corrects bullet 6 to say YTD move was nearly 2%, not about 5%
** Shares of AstraZeneca AZN.L up 3.8% at £135.46
** Stock among top three gainers on FTSE 100 .FTSE
** Company beats Q3 sales and profit forecasts and maintains 2026 outlook, with growth driven by cancer and rare-disease medicines
** Reports Q3 core earnings of $2.79 per share and revenue of $16.21 billion, beating analysts' estimates of $2.59 per share and $15.94 billion, respectively
** AstraZeneca launches $1.5 billion annual savings plan to invest in drug pipeline
** YTD, shares down nearly 2% so far this year
(Reporting by Tuhina and Raechel Thankam Job)
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)